If you have been researching compounded GLP-1 supply options for your clinic, you have almost certainly encountered the terms "503A" and "503B." These are not just regulatory labels — they describe fundamentally different legal frameworks, with different requirements, different restrictions, and different implications for your clinic's compliance posture.

Getting this distinction wrong is not a minor paperwork issue. It can mean the difference between a defensible supply chain and one that exposes your clinic to FDA enforcement, state board action, or civil liability.

Here is what every clinic owner and medical director needs to understand before placing a compounded GLP-1 order in 2026.

The Drug Quality and Security Act (DQSA) of 2013 created two distinct regulatory frameworks for compounding pharmacies under the Federal Food, Drug, and Cosmetic Act:

Section 503A governs traditional compounding pharmacies. These pharmacies compound medications for specific, identified patients based on a valid prescription from a licensed prescriber. They are primarily regulated at the state level by state boards of pharmacy, though they must also comply with federal requirements.

Section 503B governs outsourcing facilities. These are larger-scale operations that can compound drugs without patient-specific prescriptions and sell directly to healthcare facilities (including clinics and hospitals). They are registered with the FDA and subject to federal Current Good Manufacturing Practice (cGMP) standards — a significantly higher bar than 503A.

The key practical difference: 503B facilities can sell to your clinic without a prescription for each patient. 503A pharmacies cannot — every order requires a valid patient-specific prescription.

For the past several years, many clinics sourced compounded semaglutide and tirzepatide from 503B outsourcing facilities. This was legally permissible because both drugs were on the FDA's drug shortage list — a prerequisite for 503B facilities to compound and sell them.

That changed in 2025 and into 2026. The FDA removed semaglutide and tirzepatide from the shortage list, citing adequate supply of the branded products (Ozempic, Wegovy, Mounjaro, Zepbound). Once a drug is removed from the shortage list, 503B facilities generally cannot continue compounding it for sale to clinics.

The practical result: the 503B pathway for GLP-1s has largely closed for most clinics, at least for standard formulations of semaglutide and tirzepatide.

This does not mean compounded GLP-1s are unavailable. It means the primary compliant pathway has shifted back to 503A — patient-specific prescriptions through a licensed 503A pharmacy.

If your clinic has been sourcing compounded GLP-1s from a 503B facility, you need to evaluate whether that arrangement is still legally permissible given the shortage list changes. The answer depends on:

1. The specific product. Semaglutide and tirzepatide in standard formulations are generally off the shortage list. Some modified formulations (different salts, combinations) may still have a pathway, but this is a nuanced legal question that requires current guidance.

2. The 503B facility's current status. Some 503B facilities have received FDA warning letters for continuing to compound shortage-list drugs after removal. Verify that your current supplier is operating within the current regulatory framework.

3. Your state's rules. State pharmacy boards have their own requirements that layer on top of federal rules. A supply arrangement that is federally permissible may still run into state-level restrictions.

If you are uncertain, the conservative and defensible position is to transition to a licensed 503A pharmacy with a per-patient prescription model.

Operating under the 503A model requires more administrative infrastructure than bulk ordering from a 503B facility, but it is the compliant pathway for most clinics in 2026. Here is what it looks like operationally:

Your clinic must have a licensed prescriber (MD, DO, NP, PA — depending on state scope of practice rules) who can evaluate patients and issue valid prescriptions. The prescription must be based on a legitimate patient-prescriber relationship and a clinical determination that the compounded product is appropriate for that specific patient.

Every order requires a prescription tied to a specific patient. This means your clinic needs a workflow for generating, transmitting, and documenting prescriptions for each patient receiving a compounded product. This is not optional — it is the legal foundation of the 503A model.

Your 503A supply partner must hold an active pharmacy license in the state where it compounds and must be authorized to ship to your state. Many states require out-of-state pharmacies to hold a non-resident pharmacy license. Verify this before placing your first order.

Maintain records of prescriptions, dispensing, and patient consent. If your clinic is ever subject to a state board inspection or an FDA inquiry, your documentation is your defense.

Whether you are evaluating a 503A or 503B supplier, these are warning signs that a supply arrangement may not be compliant:

No prescription required. If a supplier is offering to ship compounded injectables to your clinic without requiring patient-specific prescriptions (and they are not a legitimate 503B facility operating within current FDA guidance), that is a significant red flag.

"Research use only" labeling. Some vendors market compounded products as RUO (research use only) to sidestep pharmacy licensing requirements. RUO products are not legally intended for patient administration. Using them in clinical practice creates serious liability.

Vague or unavailable licensure documentation. A compliant pharmacy will readily provide proof of state licensure, USP compliance documentation, and COAs. If a supplier is evasive about any of these, look elsewhere.

Prices that seem too good to be true. Compliant compounding — licensed facility, USP-standard clean rooms, independent lab testing, cold-chain shipping — has real costs. Suppliers offering dramatically below-market pricing are often cutting corners somewhere in the compliance chain.

No cold-chain shipping. Compounded GLP-1s and most peptides are temperature-sensitive biologics. Any supplier shipping these products without validated cold-chain packaging is not operating to an acceptable standard.

Some clinic owners view the per-patient prescription requirement as an administrative burden. In practice, it is also a compliance asset.

The prescription requirement creates a documented, patient-specific record for every product your clinic dispenses. That documentation is your evidence that the product was prescribed by a licensed provider, for a specific patient, based on a clinical evaluation. It is the paper trail that protects your clinic if you are ever questioned by a state board, an insurer, or a plaintiff's attorney.

Clinics that have operated under the 503A model with rigorous documentation have generally fared better in regulatory inquiries than those that relied on bulk ordering arrangements without clear prescription documentation.

If you are transitioning to or evaluating a 503A supply partner, these are the questions to ask:

1. Are you licensed in my state, or do you hold a non-resident pharmacy license to ship here?
2. Do you comply with USP 797 for sterile compounding? Can you provide your most recent compliance documentation?
3. Do you require a patient-specific prescription for every order?
4. What is your cold-chain shipping protocol and validation data?
5. Do you provide a COA from an independent third-party lab for each batch?
6. How do you handle state-specific regulatory requirements for my state?
7. What is your process for staying current on FDA and state board guidance?

A compliant partner answers all of these questions clearly and backs them up with documentation.

MedClinic Partners operates a B2B supply portal built around the 503A model. Every order through the portal is tied to a valid patient-specific prescription from your clinic's prescribing provider. The portal is NPI-verified, the pharmacy operates to USP 795/797 standards, and every batch ships with cold-chain packaging and independent COA documentation.

For clinics that are transitioning away from 503B sourcing or evaluating their current supply arrangements in light of the 2025-2026 shortage list changes, the portal is designed to make compliant 503A sourcing operationally straightforward.

Learn more about the 503A Clinic Supply Program and apply to the portal.

The 503A and 503B pathways are not interchangeable, and the regulatory landscape for compounded GLP-1s shifted significantly in 2025 and 2026. For most clinics, the 503A model — patient-specific prescriptions through a licensed pharmacy — is now the primary compliant pathway for sourcing compounded semaglutide, tirzepatide, and related products.

Understanding this distinction is not optional. It is the foundation of a defensible supply chain. Clinics that get it right protect their patients, their licenses, and their businesses. Clinics that do not are taking on regulatory and legal risk that is entirely avoidable.

Review your current supply arrangements. Verify your pharmacy's licensure and compliance documentation. And if you have questions about whether your current sourcing is defensible, consult with a healthcare attorney who specializes in compounding regulations.